Цефтриаксон-MIP

Основна информация

  • Търговско наименование:
  • Цефтриаксон-MIP 2 g прах за инжекционен разтвор x 10
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Цефтриаксон-MIP 2 g прах за инжекционен разтвор x 10
    България
  • Език:
  • български

Терапевтична информация

  • Каталог на резюме:
  • Ceftriaxon-MIP, 2 g powder for solution for injection x 10

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20060761
  • Дата Оторизация:
  • 29-10-2015
  • Последна актуализация:
  • 01-06-2018

Листовка за пациента

9-9-2011

Danish Pharmacovigilance Update, 18 August 2011

Danish Pharmacovigilance Update, 18 August 2011

Among the topics covered in this issue are Vimpat® 15mg/ml syrup (lacosamide) for treatment of epilepsy, which is recalled due to a quality defect and Nplate® (romiplostim), which could increase the risk of disease progression in patients with myelodysplastic syndrome (MDS).

Danish Medicines Agency

15-5-2018

Pramipexole Accord (Accord Healthcare Limited)

Pramipexole Accord (Accord Healthcare Limited)

Pramipexole Accord (Active substance: pramipexole) - Centralised - Yearly update - Commission Decision (2018)2995 of Tue, 15 May 2018

Europe -DG Health and Food Safety

3-5-2018

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Active substance: pramipexole) - Centralised - Yearly update - Commission Decision (2018)2775 of Thu, 03 May 2018

Europe -DG Health and Food Safety

2-2-2018

MiPet Easecto (Zoetis Belgium S.A.)

MiPet Easecto (Zoetis Belgium S.A.)

MiPet Easecto (Active substance: sarolaner) - New authorisation - Commission Decision (2018)656 of Fri, 02 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4732

Europe -DG Health and Food Safety

10-11-2017

Pending EC decision:  Nplate, romiplostim, Opinion date: 09-Nov-2017

Pending EC decision: Nplate, romiplostim, Opinion date: 09-Nov-2017

Europe - EMA - European Medicines Agency